vs
Side-by-side financial comparison of ARDELYX, INC. (ARDX) and ServisFirst Bancshares, Inc. (SFBS). Click either name above to swap in a different company.
ServisFirst Bancshares, Inc. is the larger business by last-quarter revenue ($159.0M vs $94.5M, roughly 1.7× ARDELYX, INC.). ServisFirst Bancshares, Inc. runs the higher net margin — 52.2% vs -39.8%, a 92.0% gap on every dollar of revenue. Over the past eight quarters, ServisFirst Bancshares, Inc.'s revenue compounded faster (17.7% CAGR vs 13.6%).
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
ServisFirst Bancshares, Inc. is a U.S.-based bank holding company operating full-service banking locations primarily across the Southeastern United States. It offers a full suite of commercial banking, consumer banking, wealth management, and mortgage lending services to small and medium-sized businesses, professional clients, and individual consumers.
ARDX vs SFBS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $94.5M | $159.0M |
| Net Profit | $-37.6M | $83.0M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | -39.8% | 52.2% |
| Revenue YoY | 27.5% | — |
| Net Profit YoY | — | 31.2% |
| EPS (diluted) | $-0.15 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $94.5M | $159.0M | ||
| Q4 25 | $125.2M | $162.2M | ||
| Q3 25 | $110.3M | $136.3M | ||
| Q2 25 | $97.7M | $132.1M | ||
| Q1 25 | $74.1M | $131.8M | ||
| Q4 24 | $116.1M | $131.9M | ||
| Q3 24 | $98.2M | $123.7M | ||
| Q2 24 | $73.2M | $114.8M |
| Q1 26 | $-37.6M | $83.0M | ||
| Q4 25 | $-407.0K | $86.4M | ||
| Q3 25 | $-969.0K | $65.6M | ||
| Q2 25 | $-19.1M | $61.4M | ||
| Q1 25 | $-41.1M | $63.2M | ||
| Q4 24 | $4.6M | $65.2M | ||
| Q3 24 | $-809.0K | $59.9M | ||
| Q2 24 | $-16.5M | $52.1M |
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | — | ||
| Q3 25 | 96.4% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | 84.3% | — | ||
| Q3 24 | 84.0% | — | ||
| Q2 24 | 87.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 66.3% | ||
| Q3 25 | 4.2% | 57.8% | ||
| Q2 25 | -14.7% | 58.0% | ||
| Q1 25 | -49.0% | 60.0% | ||
| Q4 24 | 7.0% | 60.2% | ||
| Q3 24 | 2.3% | 58.5% | ||
| Q2 24 | -18.6% | 58.0% |
| Q1 26 | -39.8% | 52.2% | ||
| Q4 25 | -0.3% | 59.0% | ||
| Q3 25 | -0.9% | 48.1% | ||
| Q2 25 | -19.5% | 46.5% | ||
| Q1 25 | -55.5% | 48.0% | ||
| Q4 24 | 4.0% | 52.9% | ||
| Q3 24 | -0.8% | 48.4% | ||
| Q2 24 | -22.5% | 45.4% |
| Q1 26 | $-0.15 | $1.52 | ||
| Q4 25 | $-0.01 | $1.58 | ||
| Q3 25 | $0.00 | $1.20 | ||
| Q2 25 | $-0.08 | $1.12 | ||
| Q1 25 | $-0.17 | $1.16 | ||
| Q4 24 | $0.01 | $1.19 | ||
| Q3 24 | $0.00 | $1.10 | ||
| Q2 24 | $-0.07 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.1M | $1.8B |
| Total DebtLower is stronger | $203.5M | — |
| Stockholders' EquityBook value | $148.6M | $1.9B |
| Total Assets | $504.5M | $18.2B |
| Debt / EquityLower = less leverage | 1.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $238.1M | $1.8B | ||
| Q4 25 | $68.0M | — | ||
| Q3 25 | $42.7M | — | ||
| Q2 25 | $90.0M | — | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $64.9M | — | ||
| Q3 24 | $47.4M | — | ||
| Q2 24 | $41.9M | — |
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | — | ||
| Q3 25 | $202.1M | — | ||
| Q2 25 | $201.4M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | $150.9M | — | ||
| Q3 24 | $100.7M | — | ||
| Q2 24 | $100.2M | — |
| Q1 26 | $148.6M | $1.9B | ||
| Q4 25 | $166.9M | $1.8B | ||
| Q3 25 | $154.3M | $1.8B | ||
| Q2 25 | $139.5M | $1.7B | ||
| Q1 25 | $145.7M | $1.7B | ||
| Q4 24 | $173.3M | $1.6B | ||
| Q3 24 | $158.3M | $1.6B | ||
| Q2 24 | $147.0M | $1.5B |
| Q1 26 | $504.5M | $18.2B | ||
| Q4 25 | $501.6M | $17.7B | ||
| Q3 25 | $486.2M | $17.6B | ||
| Q2 25 | $466.8M | $17.4B | ||
| Q1 25 | $410.2M | $18.6B | ||
| Q4 24 | $435.8M | $17.4B | ||
| Q3 24 | $367.9M | $16.4B | ||
| Q2 24 | $343.5M | $16.0B |
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
SFBS
| Net Interest Income | $148.1M | 93% |
| Noninterest Income | $10.8M | 7% |
